8th IAS Conference on HIV Pathogenesis, Treatment and Prevention*

Download All
July 19-22, 2015; Vancouver, Canada
CCO is the official provider of online scientific analysis for the 2015 International AIDS Society meeting, through Capsule Summaries, downloadable slides, and faculty analysis of key studies.

HIV Treatment Trials


In this landmark women-only study, patients assigned to receive the boosted PI were more likely to discontinue treatment for adverse events.

Released: July 23, 2015

Landmark randomized trial produces clear evidence of benefits of earlier ART initiation.

Released: July 23, 2015

Discontinuation rates due to toxicity significantly lower with lower atazanavir/ritonavir dose.

Released: July 24, 2015

Treatment switch associated with lower rate of discontinuation for adverse events and improvements in renal and bone markers.

Released: July 24, 2015

Switch to EVG/COBI/FTC/TAF from TDF-containing regimens also associated with increased bone mineral density and increases in total cholesterol, LDL cholesterol, and triglycerides.

Released: July 24, 2015

Week 24 virologic and immunologic outcomes were similar between arms; doravirine was associated with fewer CNS adverse events vs efavirenz.

Released: July 27, 2015

Substantial hyperbilirubinemia with RTV-containing regimens.

Released: July 24, 2015

However, all 3 cases of virologic rebound and 1 case of central nervous system escape occurred in the monotherapy switch arm.

Released: July 28, 2015

In this case-controlled study, HIV-related factors predicted risk of bone loss in first 96 weeks but not during later follow-up.

Released: July 24, 2015

Treatment generally well tolerated with evidence of improvements in markers of HBV and liver disease in this coinfected population.

Released: July 26, 2015

A low CD4+ cell count was also significantly associated with differences in hip bone mineral density changes.

Released: July 27, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Bristol-Myers Squibb
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.